INV-8989
/ Ionova Life Sci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 11, 2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
(clinicaltrials.gov)
- P1/2 | N=178 | Recruiting | Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Biliary Cancer • Colon Cancer • Colorectal Cancer • Endometrial Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Rectal Cancer • Solid Tumor • KRAS
May 29, 2026
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
(clinicaltrials.gov)
- P1/2 | N=178 | Not yet recruiting | Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
New P1/2 trial • Biliary Cancer • Colon Cancer • Colorectal Cancer • Endometrial Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Rectal Cancer • Solid Tumor • KRAS
1 to 2
Of
2
Go to page
1